Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SELE | P16581 | 1/20 | 0.30 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12651908 | 0.89 | CYP1A2 (0.36) | MAPK1CYP1A2TMIGD3CYP2C9ADORA1 | |
| SCHEMBL120586 | 0.82 | PKM (0.50) | PKMNPSR1RXFP1ALDH1A1 | |
| SCHEMBL16004512 | 0.80 | MAPK1 (0.37) | PKMNPSR1RXFP1MAPK1CYP1A2 | |
| SCHEMBL22674913 | 0.79 | PKM (0.36) | PKMNPSR1RXFP1 | |
| SCHEMBL15926111 | 0.78 | GPR35 (0.35) | PKMNPSR1RXFP1 | |
| SCHEMBL15275809 | 0.77 | SELE (0.38) | MAPK1CYP1A2TMIGD3CYP2C9ADORA1 | |
| SCHEMBL12651686 | 0.76 | MAPK1 (0.33) | MAPK1CYP1A2TMIGD3CYP2C9ADORA1 | |
| SCHEMBL18179593 | 0.75 | CYP1A2 (0.35) | MAPK1CYP1A2TMIGD3CYP2C9ADORA1 | |
| SCHEMBL18876157 | 0.75 | MAPK1 (0.32) | PKMNPSR1RXFP1MAPK1GAA | |
| SCHEMBL22845454 | 0.75 | MAPK1 (0.32) | MAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013028441-A2 | NEW POLY(HETEROARYLENE VINYLENE)S BASED ON DIKETOPYRROLOPYRROLE | UNIVERSITY OF WASHINGTON (US) | 2013-02-28 | — | — | WO | disclosed |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED | 2012-01-26 | — | — | US | disclosed |
| US-7998540-B2 | Substituted anthracenes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-08-16 | — | — | US | disclosed |
| US-20070014934-A1 | Substituted anthracenes | MERCK PATENT GMBH (DE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | GPR35, GPR65, GPR68 | PKM 1825/4885NPSR1 410/4885RXFP1 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.